儿童多发性硬化治疗前血清神经丝轻链水平、早期疾病严重程度与治疗反应
该回顾性队列研究纳入德国哥廷根儿童与青少年多发性硬化中心178例未治疗患儿,分析治疗前血清神经丝轻链(sNfL)与早期疾病严重程度及治疗结局的关联。结果显示治疗前sNfL水平与MRI活动度、复发率及一线治疗失败相关,高水平sNfL与未来升级治疗风险增加及复发后恢复不良相关。
要点
- 80%患儿治疗前sNfL高于健康对照≥90百分位(中位数21.1 pg/mL)。
- 治疗前sNfL与既往复发次数、短首发间期、高T2病灶数及近期钆增强病灶显著相关。
- sNfL低于7.5 pg/mL时未来升级治疗OR为0.14,高于15 pg/mL时OR为6.38。
核心结论
- 治疗前sNfL是儿童多发性硬化潜在疾病活动的有价值生物标志物。
- 治疗前sNfL对一线治疗反应及未来升级治疗必要性有预测价值。
- 复发期间高sNfL水平与该年龄组恢复不良相关。
研究设计与样本
- 德国哥廷根儿童与青少年多发性硬化中心的回顾性队列研究。
- 纳入标准为符合McDonald标准的多发性硬化诊断、发病年龄<18岁且有治疗前血清样本。
- 共纳入178例患者(女性116例[65%]),平均采样年龄14.3岁。
- sNfL采用单分子阵列分析检测。
主要发现
- 80%患者治疗前sNfL高于健康对照≥90百分位(中位数21.1 pg/mL),与年龄负相关。
- 治疗前sNfL与性别、寡克隆带状态或体重指数无相关性。
- 高治疗前sNfL与既往复发次数多、首发间期短、T2病灶数高及近期钆增强病灶显著相关。
- sNfL水平反映MRI活动性较临床活动性更强。
- 治疗前sNfL与一线注射治疗期间复发率及新发/扩大T2病灶发生显著相关。
关键数值与推荐
- sNfL低于7.5 pg/mL时未来升级治疗OR为0.14,高于15 pg/mL时OR为6.38。
- 治疗前sNfL中位数为21.1 pg/mL,80%患者高于健康对照≥90百分位。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: High disease activity and frequent therapy failure in pediatric multiple sclerosis (MS) make prognostic biomarkers urgently needed. We investigated whether serum neurofilament light chain (sNfL) levels in treatment-naive pediatric patients with MS are associated with early disease severity and indicate treatment outcomes. METHODS: A retrospective cohort study of patients seen in the Göttingen Center for MS in Childhood and Adolescence, Germany. Inclusion criteria were MS diagnosis according to the McDonald criteria, MS onset <18 years, and available pretreatment serum sample. sNfL levels were analyzed using a single-molecule array assay. Associations with clinical and MRI evidence of disease severity at sampling were evaluated using the Spearman correlations and nonparametric tests for group comparisons. Correlations between pretreatment sNfL and annualized relapse and new T2 lesion rate on first-line therapy, and odd ratios for switch to high-efficacy therapy were assessed. RESULTS: A total of 178 patients (116 women [65%]) with a mean sampling age of 14.3 years were included in the study. Pretreatment sNfL levels were above the ≥90th percentile reported for healthy controls in 80% of patients (median 21.1 pg/mL) and correlated negatively with age, but no correlation was seen with sex, oligoclonal band status, or body mass index. High pretreatment sNfL levels correlated significantly with a high number of preceding relapses, a shorter first interattack interval, a high T2 lesion count, and recent gadolinium-enhancing lesions. Of interest, sNfL levels reflected more strongly MRI activity rather than clinical activity. Pretreatment sNfL levels also correlated significantly with the relapse rate and occurrence of new/enlarging T2 lesions while on first-line injectable therapy. Odds of future therapy escalation increased from 0.14 for sNfL below 7.5 pg/mL to 6.38 for sNfL above 15 pg/mL. In patients with a recent relapse, higher sNfL levels were associated with poorer recovery 3 months after attack. DISCUSSION: The results of this study have 3 important implications: First, pretreatment sNfL levels are a valuable biomarker for underlying disease activity in pediatric patients with MS. Second, pretreatment sNfL levels in pediatric patients with MS have a predictive value for the response to first-line therapy and the necessity of future therapy escalation. Third, high sNfL levels during a relapse are associated with poor recovery in this age group.
引用
- Huppke B, Reinert MC, Hummel-Abmeier H, et al. Pretreatment Neurofilament Light Chain Serum Levels, Early Disease Severity, and Treatment Response in Pediatric Multiple Sclerosis. Neurology. 2023. PMID: 37748882. doi:10.1212/WNL.0000000000207791
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。